For acquired TTP, plasma exchange (1.5x plasma volume, daily) is often required to replenish the missing ADAMTS13 protease and to remove autoantibodies that inhibit plasma ADAMTS13 activity [22]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.